IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.648
AS - Asia 3.970
EU - Europa 2.918
SA - Sud America 709
AF - Africa 301
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 19.555
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.527
SG - Singapore 1.606
RU - Federazione Russa 766
VN - Vietnam 696
CN - Cina 609
BR - Brasile 549
HK - Hong Kong 514
IT - Italia 453
IE - Irlanda 434
SE - Svezia 259
DE - Germania 242
FR - Francia 217
CI - Costa d'Avorio 191
GB - Regno Unito 178
IN - India 139
UA - Ucraina 119
BD - Bangladesh 74
FI - Finlandia 64
JP - Giappone 51
CA - Canada 47
AR - Argentina 46
MX - Messico 45
CO - Colombia 40
NL - Olanda 34
ZA - Sudafrica 34
PL - Polonia 31
IQ - Iraq 30
KR - Corea 30
TR - Turchia 27
ID - Indonesia 26
MA - Marocco 24
PH - Filippine 22
EC - Ecuador 21
PK - Pakistan 21
ES - Italia 20
BE - Belgio 19
UZ - Uzbekistan 18
VE - Venezuela 18
MY - Malesia 14
EE - Estonia 13
DK - Danimarca 12
CL - Cile 11
EG - Egitto 11
SA - Arabia Saudita 11
TN - Tunisia 11
TH - Thailandia 9
AU - Australia 8
BO - Bolivia 8
IL - Israele 8
JO - Giordania 8
KZ - Kazakistan 8
RO - Romania 7
AT - Austria 6
BG - Bulgaria 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
PY - Paraguay 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
DZ - Algeria 5
KG - Kirghizistan 5
LB - Libano 5
NP - Nepal 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
ET - Etiopia 4
KE - Kenya 4
LT - Lituania 4
NI - Nicaragua 4
OM - Oman 4
AL - Albania 3
AO - Angola 3
BH - Bahrain 3
CH - Svizzera 3
GA - Gabon 3
HN - Honduras 3
LU - Lussemburgo 3
LY - Libia 3
PE - Perù 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
GD - Grenada 2
GE - Georgia 2
HR - Croazia 2
HU - Ungheria 2
IS - Islanda 2
KH - Cambogia 2
PA - Panama 2
RS - Serbia 2
SN - Senegal 2
ZW - Zimbabwe 2
AD - Andorra 1
BB - Barbados 1
BN - Brunei Darussalam 1
BT - Bhutan 1
BY - Bielorussia 1
Totale 19.537
Salva come PNG Salva come JPEG
Città #
Ashburn 1.781
Des Moines 1.473
Singapore 1.191
Chandler 1.178
Fairfield 666
Dallas 569
San Jose 526
Hong Kong 501
Dublin 425
Wilmington 347
Boardman 322
Woodbridge 282
Houston 261
Seattle 256
The Dalles 246
Ho Chi Minh City 224
Cambridge 214
Jacksonville 200
Abidjan 191
New York 169
Lawrence 167
Princeton 167
Lauterbourg 158
Los Angeles 152
Beijing 150
Hanoi 150
San Mateo 142
Ann Arbor 135
Moscow 128
Council Bluffs 106
San Diego 102
Munich 81
Washington 73
Redmond 72
Pune 65
Milan 61
Columbus 55
São Paulo 54
London 48
Santa Clara 48
Chicago 46
Orem 45
Tokyo 44
Hefei 40
Helsinki 39
Da Nang 36
Haiphong 36
Ancona 33
Miano 33
Falls Church 31
Buffalo 30
Shanghai 29
Wuhan 29
Warsaw 27
Rome 26
Frankfurt am Main 24
Guangzhou 24
Turku 24
Brooklyn 23
Manchester 23
Montreal 23
Stockholm 22
Phoenix 21
Denver 20
Brussels 19
Norwalk 19
San Francisco 19
Turin 19
Atlanta 18
Chennai 18
Amsterdam 17
Seoul 17
Dhaka 16
Mexico City 16
Tashkent 16
Jiaxing 15
Rio de Janeiro 15
Boston 13
Brasília 13
Can Tho 13
Johannesburg 12
Poplar 12
Baghdad 11
Curitiba 11
Jakarta 11
Medellín 11
Porto Alegre 11
Bogotá 10
Cape Town 10
Hải Dương 10
Prescot 10
Salt Lake City 10
Thái Nguyên 10
Bologna 9
Elk Grove Village 9
Forlì 9
Istanbul 9
Tampa 9
Toronto 9
Amman 8
Totale 14.328
Salva come PNG Salva come JPEG
Nome #
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 223
Immunotherapy in genitourinary cancers: Where are we going? 208
Are liver nested stromal epithelial tumors always low aggressive? 201
Designing novel immunocombinations in metastatic renal cell carcinoma 201
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 198
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 195
Biomarkers of angiogenesis and clinical outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Randomized Phase III METEOR Trial 194
Predicting future cancer burden in the United States by artificial neural networks 190
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 183
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 178
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 173
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 169
Exploring the Spectrum of Kidney Ciliopathies 167
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 164
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 161
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 161
An update on investigational therapies that target STAT3 for the treatment of cancer 158
Microbiome and cancers, with focus on genitourinary tumors 155
Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer 153
Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology 153
Morphologic Variants of Epithelial and Neuroendocrine Tumors of the Prostate. The Pathologist's Point of View 152
Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter 152
Molecular characterization of testicular germ cell tumors using tissue microdissection 147
Bone targeting agents in patients with metastatic prostate cancer: State of the art 147
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 146
The role of obesity in renal cell carcinoma patients: Clinical-pathological implications 146
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 145
Is There a Role for Immunotherapy in Prostate Cancer? 143
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 142
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 141
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 140
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 138
Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians 137
Molecular diagnostics in uro-oncology 136
Pd-l1 inhibitors for the treatment of prostate cancer 136
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 135
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 134
Targeted therapy for solid tumors and risk of hypertension: a meta-analysis of 68077 patients from 93 phase III studies 132
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 132
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 132
Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers 132
Epigenetic modifications and modulators in prostate cancer 131
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 131
Predicting biochemical recurrence after radical prostatectomy: the role of prognostic grade group and index tumor nodule 131
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 130
Variants and Variations in Epithelial Renal Cell Tumors in Adults: The Pathologist's Point of View 130
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype 130
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer 129
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 129
The identification of immunological biomarkers in kidney cancers 128
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 127
From undergraduate medical school student to visible pathologist 127
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 127
The human microbiota and prostate cancer: Friend or foe? 126
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 126
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading 125
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 124
Expression of miR-100 and miR-138 as prognostic biomarkers in non-muscle-invasive bladder cancer 124
Genitourinary tumors: Update on molecular biomarkers for diagnosis, prognosis and prediction of response to therapy 124
RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications 124
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 124
Biphasic Tumors of the Urogenital Tract: Selected Topics 124
An update on immunotherapy in uro-oncology 123
Current application of the enhanced recovery after surgery protocol for patients undergoing radical cystectomy: lessons learned from European excellence centers 122
Immune checkpoint inhibitors for the treatment of bladder cancer 121
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 121
Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice 120
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution 120
Prostate cancer with cribriform morphology: diagnosis, aggressiveness, molecular pathology and possible relationships with intraductal carcinoma 120
Pathology and molecular updates in tumors of the prostate: towards a personalized approach. 119
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 119
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 119
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 119
Syndrome of inappropriate antidiuresis in prostate adenocarcinoma with neuroendocrine differentiation: a case report and literature review 118
Liquid biopsy in the clinical management of bladder cancer: current status and future developments 118
Prostate cancer grading in 2018: Limitations, implementations, cribriform morphology, and biological markers 118
Circulating tumor dna testing for homology recombination repair genes in prostate cancer: From the lab to the clinic 118
Renal Cell Carcinoma: genomic landscape and clinical implications 117
Variants of Bladder Cancer: The Pathologist's Point of View 116
New prostate cancer targets for diagnosis, imaging, and therapy: Focus on prostate-specific membrane antigen 114
Pathology without microscope: From a projection screen to a virtual slide 114
Variants and new entities of bladder cancer 113
Treating prostate cancer by antibody-drug conjugates 113
Epigenetic modulations and lineage plasticity in advanced prostate cancer 112
Agent-Based Learning Model for the Obesity Paradox in RCC 112
Molecular Pathology of Urothelial Carcinoma 112
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 111
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 111
Narrative review: Predicting future molecular and clinical profiles of prostate cancer in the United States 111
Exploring small extracellular vesicles for precision medicine in prostate cancer 110
New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents? 110
Digital frozen section of the prostate surface during radical prostatectomy: a novel approach to evaluate surgical margins 110
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 110
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 109
Long Non-coding RNAs in prostate cancer with emphasis on second chromosome locus associated with prostate-1 expression 109
PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: the Role of PD-L1 Assay 107
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 107
INTRADUCTAL CARCINOMA IN LOW- AND INTERMEDIATE-RISK PROSTATE CANCER: PATHOLOGICAL AND CLINICAL RELEVANCE 107
Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer 106
Update on Prostate Cancer Diagnosis, Prognosis, and Prediction to Response to Therapy 106
Totale 13.543
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.749
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.749
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202143 0 0 0 0 0 0 0 0 0 0 0 43
2021/20221.512 267 171 79 23 50 179 28 90 128 116 87 294
2022/20234.130 266 288 156 313 218 1.705 3 234 680 16 178 73
2023/20241.610 282 45 138 162 248 358 22 49 5 57 24 220
2024/20252.948 376 229 35 52 103 121 226 107 750 305 259 385
2025/20267.210 396 441 441 288 1.024 469 1.490 741 733 669 178 340
Totale 19.790